Skip to main content

Tag: cancer

Study Finds That CBD Oil Mitigates Chemotherapy-Induced Neuropathy

I have said it before and I will say it again – cancer is one of the worst things on earth. If you or a loved one has ever battled cancer, then you know firsthand how awful cancer can be. Unfortunately, it’s something that millions of people die from every year, with millions more being diagnosed during the same duration of time.

The World Health Organization estimates that in 2020 alone, over 10 million people died from cancer around the world, with cancer being to blame for one out of every six deaths on earth.

Various treatments are currently incorporated into strategies to battle cancer, with one of the most common forms of treatment being chemotherapy. Chemotherapy is a drug treatment involving powerful chemicals that aim to kill fast-growing cells in the human body.

Chemotherapy can be effective in some cases, but it yields numerous side effects to some degree in all cases. One common side effect is neuropathy. Chemotherapy can damage the nervous system around the brain and spinal cord.

Fortunately for chemotherapy patients that must undergo the treatment, cannabidiol appears to help mitigate chemotherapy-induced neuropathy according to a recent study out of Denmark. Below is more information about it via a news release from NORML:

Roskilde, Denmark: The short-term administration of CBD oil extracts is safe and effective in patients suffering from chemotherapy-induced peripheral neuropathy (CIPN), according to data published in the journal Supportive Care in Cancer.

Danish investigators assessed the twice daily administration of CBD oil (300 mg/daily) in patients receiving either oxaliplatin or paclitaxel-based chemotherapy. Subjects used CBD for a period of eight days immediately following their first cycle of chemotherapy. Patients outcomes were compared to those of similarly matched controls.

Researchers reported that the use of CBD was associated with pronounced improvements in patients’ pain-related outcomes, including cold sensitivity and throat discomfort.

“CBD attenuated early symptoms of CIPN with no major safety concerns,” they concluded. “Long-term follow-up is ongoing. Results should be confirmed in a larger, randomized study.”

Separate studies have identified an association between patients’ long-term use of cannabis products and statistical improvements in cancer-related symptoms as well as significant reductions in their use of prescription painkillers.

Full text of the study, “Oral cannabidiol for prevention of acute and transient chemotherapy-induced peripheral neuropathy,” appears in Supportive Care in Cancer.

Prior Cannabis Use Inversely Associated With Urological Cancers

Urological cancers can occur in both men and women and are caused by abnormal cell growths in the organs of the urinary tract and the male reproductive tract.

The specific types of urological cancers can affect the kidneys, ureter, bladder, urethra, prostate, and/or testicles. The most common type of urologic cancer is bladder cancer.

Various things can contribute to the development of urological cancers, including genetics and environmental factors, with tobacco use being a notable contributing factor.

Common treatments include surgery, radiation, chemotherapy, and in some cases immunotherapy. Past cannabis use is associated with a lower risk of urological cancers according to a new study. Below is more information about it via a news release from NORML:

London, United Kingdom: Women with a past history of cannabis use are at lower risk of suffering from certain types of urological cancers, according to population-based data published in the journal Cancer Medicine.

An international team of researchers from China, France, and the United Kingdom assessed the relationship between cannabis use and cancer risk in a cohort of more than 151,000 subjects.

Investigators reported, “Previous use of cannabis was a significant protective factor” in women against renal cell carcinoma (RCC) and bladder cancer (BCa). They further reported that “previous cannabis use was a significant protective factor for PCa (prostate cancer) in men with a history of tobacco smoking.” A history of cannabis use had a null effect on rates of testicular cancer.

Authors concluded: “In the current study, we investigated the association between the use of cannabis and the risk of urological cancers. We observed that: (1) previous use of cannabis was a significant inverse association with both RCC and PCa; (2) cannabis use was associated with the lower risk of BCa in the point estimates; (3) the protective effect of cannabis on RCC and BCa was significant for females but not for males; (4) cannabis use had a causal effect on lower incidence of RCC.”

Prior studies have similarly identified an inverse association between a past history of cannabis use and the development of certain types of cancers, including bladder cancer, liver cancer, and head and neck cancers.

Full text of the study, “Association between cannabis use with urological cancers: A population-based cohort study and mendelian randomization study in the UK biobank,” appears in Cancer Medicine.

Cancer Patients Reduced Prescriptions, Improved Symptoms After Long-Term Cannabis Use

If you have battled cancer, or know someone that has, then you are completely aware of how awful of a condition it can be. To make matters worse, many of the current treatments for cancer come with a number of terrible side effects.

The cannabis plant has helped many cancer patients over many years in various ways, and according to a recent study in Israel, it is associated with reduced prescriptions and improvements in symptoms. Below is more information about it via a news release from NORML:

Haifa, Israel: The use of cannabis products over a six-month period is associated with statistical improvements in cancer-related symptoms as well as significant reductions in subjects’ use of prescription painkillers, according to longitudinal data published in the journal Frontiers in Pain Research.

Israeli researchers assessed the long-term use of cannabis in a cohort of several hundred oncology patients.

Consistent with studies of other patient cohorts, cannabis use was associated with symptom mitigation, improved quality of life, and reduced prescription drug use. Among those participants who completed the trial, nearly half ceased their use of analgesics.

Authors concluded: “The main finding of the current study is that most cancer comorbid symptoms improved significantly during six months of MC [medical cannabis] treatment. … Additionally, we found that MC treatment in cancer patients was well tolerated and safe. … In conclusion, this prospective, comprehensive and large-scale cohort demonstrated an overall mild to modest long-term statistical improvement of all investigated measures including pain, associated symptoms and, importantly, reduction in opioid (and other analgesics) use.”

Full text of the study, “The effectiveness and safety of medical cannabis for treating cancer related symptoms in oncology patients,” appears inFrontiers in Pain ResearchAdditional information is available from the NORML fact sheet, “Relationship Between Marijuana and Opioids.”

Cannabis May Help Reduce Refractory Chemotherapy-Induced Nausea

According to the World Cancer Research Fund, as many as 18 million people were diagnosed with cancer worldwide in just 2018 alone. It’s a very sad statistic, and will never quantify the pain and suffering that cancer patients have to endure.

Unfortunately, there is no cure for cancer. Cancer comes in different forms, and there are different treatments available depending on the patient’s situation.

A common form of cancer treatment is chemotherapy. Anyone that has endured chemotherapy treatment will be quick to tell you that it is absolutely awful, resulting in all types of side effects including severe nausea.

Fortunately for suffering cancer patients, the results of a new study indicate that cannabis extracts may be able to help reduce refractory chemotherapy-induced nausea. Below is more information about it via a news release from NORML:

The adjunctive use of cannabis extracts significantly reduces symptoms in patients with treatment-resistant chemotherapy-induced nausea, according to clinical trial data published in the journal Annals of Oncology.

Australian researchers compared cannabis extracts (oral capsules containing 2.5mg of THC and 2.5mg of CBD) versus placebo in a cohort of 72 patients with chemotherapy-induced nausea and vomiting (CINV).

Researchers reported that the adjunctive use of cannabis extracts was associated with reductions in patients’ nausea and vomiting, and also with improvements in subjects’ overall quality of life. Although the majority of patients did report side-effects, these effects were largely limited to non-serious events such as sedation and dizziness.

They concluded: “The oral THC:CBD cannabis extract was active and tolerable in preventing CINV, when combined with guideline-consistent antiemetic prophylaxis for a study population with refractory CINV. … Further research is necessary to determine the significance and durability of improvements observed in specific AQOL-8D [quality of life] dimensions.”

Cannabis extracts containing equal ratios of THC and CBD are already available in many countries by prescription under the brand name Sativex. The substance is not legally available in the United States. By contrast, oral synthetic THC, marketed under the brand name Marinol, is FDA-approved in the US for the treatment of nausea and vomiting associated with cancer chemotherapy.

 

Cannabis Use Not Associated With Elevated Risk Of Secondary Cancer Per Study

It is estimated that roughly 4% of all cancer patients suffer from head and/or neck cancer. As with any form of cancer, head and neck cancer are absolutely awful for anyone to have to battle.

The results of a recent cannabis study provide some encouraging news for those that suffer from those particular forms of cancer. Below is more information about it via a news release from our friends at NORML:

Patients with head and neck cancers who possess a history of cannabis use are not at an increased risk of developing a secondary cancer diagnosis, according to data published in the journal Cureus.

A team of researchers affiliated with McMaster University, the University of Toronto, and the University of British Columbia assessed the association between cannabis smoking and the risk of developing a second primary squamous cell carcinoma in patients previously diagnosed with head and neck cancer.

Investigators reported that those who consumed cannabis “showed lower odds of developing SPC” compared to non-users.

“These results suggest that cannabis behaves differently than tobacco smoking,” they concluded. “Our results are consistent with the theory that cannabis is not carcinogenic and hence would not follow patterns of field cancerization.”

The study’s findings are consistent with those of prior papers concluding that cannabis smoke and tobacco smoke are not equally carcinogenic and that marijuana smoke exposure is not associated with many types of tobacco-related diseases, such as lung cancer and COPD.

Full text of the study, “Rate of second primary head and neck cancer with cannabis use,” appears in Cureus. Additional information is available from the NORML white paper, “All Smoke Is Not Created Equal.”